DrugCite
Search

UFT

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Uft Adverse Events Reported to the FDA Over Time

How are Uft adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Uft, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Uft is flagged as the suspect drug causing the adverse event.

Most Common Uft Adverse Events Reported to the FDA

What are the most common Uft adverse events reported to the FDA?

Diarrhoea
54 (7.03%)
Alanine Aminotransferase Increased
26 (3.39%)
Hepatic Function Abnormal
26 (3.39%)
Aspartate Aminotransferase Increase...
25 (3.26%)
Vomiting
20 (2.6%)
Interstitial Lung Disease
18 (2.34%)
Pyrexia
18 (2.34%)
Anorexia
17 (2.21%)
Blood Lactate Dehydrogenase Increas...
14 (1.82%)
Nausea
14 (1.82%)
Blood Bilirubin Increased
13 (1.69%)
Show More Show More
Gamma-glutamyltransferase Increased
12 (1.56%)
Pancytopenia
12 (1.56%)
White Blood Cell Count Decreased
11 (1.43%)
Dehydration
10 (1.3%)
Rash
10 (1.3%)
Renal Impairment
10 (1.3%)
Disseminated Intravascular Coagulat...
9 (1.17%)
Sepsis
9 (1.17%)
Liver Disorder
8 (1.04%)
Malignant Neoplasm Progression
8 (1.04%)
Stomatitis
8 (1.04%)
Acute Myeloid Leukaemia
6 (.78%)
Enterocolitis
6 (.78%)
Haemoglobin Decreased
6 (.78%)
Malaise
6 (.78%)
Red Blood Cell Count Decreased
6 (.78%)
Anaemia
5 (.65%)
Blood Alkaline Phosphatase Increase...
5 (.65%)
Decreased Appetite
5 (.65%)
Multi-organ Failure
5 (.65%)
Ascites
4 (.52%)
Bone Marrow Failure
4 (.52%)
Carbohydrate Antigen 15-3 Increased
4 (.52%)
Febrile Neutropenia
4 (.52%)
Headache
4 (.52%)
Hypovolaemic Shock
4 (.52%)
Melaena
4 (.52%)
Metastases To Liver
4 (.52%)
Palmar-plantar Erythrodysaesthesia ...
4 (.52%)
Platelet Count Decreased
4 (.52%)
Rhabdomyolysis
4 (.52%)
Abdominal Pain
3 (.39%)
Abdominal Pain Upper
3 (.39%)
Acute Myocardial Infarction
3 (.39%)
Blood Creatinine Increased
3 (.39%)
Blood Potassium Decreased
3 (.39%)
Cerebral Haemorrhage
3 (.39%)
Colon Cancer
3 (.39%)
Escherichia Infection
3 (.39%)
Escherichia Sepsis
3 (.39%)
Fatigue
3 (.39%)
Haematocrit Decreased
3 (.39%)
Haemorrhage
3 (.39%)
Hepatitis
3 (.39%)
Hypotension
3 (.39%)
Idiopathic Thrombocytopenic Purpura
3 (.39%)
Infective Spondylitis
3 (.39%)
Intestinal Ischaemia
3 (.39%)
Jaundice
3 (.39%)
Leukopenia
3 (.39%)
Lymphocyte Count Decreased
3 (.39%)
Metastases To Lung
3 (.39%)
Non-small Cell Lung Cancer
3 (.39%)
Pain In Extremity
3 (.39%)
Rectal Cancer
3 (.39%)
Septic Shock
3 (.39%)
Sick Sinus Syndrome
3 (.39%)
Thrombocytopenia
3 (.39%)
Weight Decreased
3 (.39%)
Alopecia
2 (.26%)
Asthenia
2 (.26%)
Blood Culture Positive
2 (.26%)
Blood Pressure Decreased
2 (.26%)
Blood Urea Increased
2 (.26%)
Blood Uric Acid Increased
2 (.26%)
Carcinoembryonic Antigen Increased
2 (.26%)
Cardio-respiratory Arrest
2 (.26%)
Colonic Obstruction
2 (.26%)
Condition Aggravated
2 (.26%)
Cystitis Haemorrhagic
2 (.26%)
Death
2 (.26%)
Diarrhoea Haemorrhagic
2 (.26%)
Dizziness
2 (.26%)
Drug Interaction
2 (.26%)
Drug Toxicity
2 (.26%)
Dysphoria
2 (.26%)
Eosinophil Count Increased
2 (.26%)
Eosinophilic Pneumonia
2 (.26%)
Gait Disturbance
2 (.26%)
Gastrointestinal Haemorrhage
2 (.26%)
Gastrointestinal Mucosal Necrosis
2 (.26%)
Haemorrhage Subcutaneous
2 (.26%)
Hydronephrosis
2 (.26%)
Hyperthermia
2 (.26%)
Hyponatraemia
2 (.26%)
Ileitis
2 (.26%)
Intentional Overdose
2 (.26%)
Lethargy
2 (.26%)
Leukaemia
2 (.26%)
Listless
2 (.26%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Uft, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Uft is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Uft

What are the most common Uft adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Uft, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Uft is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Uft According to Those Reporting Adverse Events

Why are people taking Uft, according to those reporting adverse events to the FDA?

Breast Cancer
62
Colon Cancer
54
Rectal Cancer
37
Gastric Cancer
16
Metastatic Renal Cell Carcinoma
15
Prostate Cancer Stage Iv
14
Show More Show More
Colorectal Cancer
12
Lung Neoplasm Malignant
11
Large Intestine Carcinoma
10
Colorectal Cancer Metastatic
9
Hepatic Neoplasm Malignant
8
Drug Use For Unknown Indication
8
Chemotherapy
7
Lip And/or Oral Cavity Cancer
7
Tongue Neoplasm Malignant Stage Uns...
6
Prostate Cancer
6
Prostate Cancer Stage Iii
5
Lung Cancer Metastatic
5
Metastatic Gastric Cancer
5
Non-small Cell Lung Cancer
5
Bladder Cancer
5
Bile Duct Cancer
4
Oropharyngeal Cancer Stage Unspecif...
4
Renal Cell Carcinoma Stage Iv
4
Nasopharyngeal Cancer
4
Renal Cell Carcinoma
3
Lung Adenocarcinoma
3
Lung Adenocarcinoma Recurrent
3
Colon Cancer Metastatic
3
Hypopharyngeal Cancer
2
Rectal Cancer Recurrent
2
Postoperative Care
2
Gum Neoplasm Malignant Stage Unspec...
2
Prostate Cancer Recurrent
2
Ureteric Cancer
2
Metastases To Liver
2
Bile Duct Cancer Recurrent
2
Squamous Cell Carcinoma
2
Rectal Cancer Metastatic
2
Carcinoma
1
Prophylactic Chemotherapy
1
Breast Cancer Recurrent
1
Metastases To Lung
1
Prostate Cancer Metastatic
1
Pagets Disease Of The Breast
1
Oesophageal Carcinoma
1
Ill-defined Disorder
1
Lung Squamous Cell Carcinoma Recurr...
1
Neoplasm Malignant
1
Gastric Cancer Stage Iv
1
Gastrointestinal Carcinoma
1

Uft Case Reports

What Uft safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Uft. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Uft.